Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s

Obesity Increases the Production of Proinflammatory Mediators from Adipose Tissue T Cells and Compromises TCR Repertoire Diversity: Implications for Systemic Inflammation and Insulin Resistance

(2010) H. Yang et al.   JOURNAL OF IMMUNOLOGY

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy

(2009) Regje ME Blümer et al.   AIDS

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

(2009) Richard H Haubrich et al.   AIDS

Changes in Body Composition with Ritonavir‐Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96‐Week Randomized, Controlled Study

(2009) Grace McComsey et al.   CLINICAL INFECTIOUS DISEASES

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

(2008) Andrew Carr et al.   AIDS

Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy

(2008) Ksenia Sevastianova et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

(2008) S. De Wit et al.   DIABETES CARE